GSK sees strong Japan performance as foundation for new investments
This article was originally published in Scrip
Executive Summary
There were no two ways about it, GlaxoSmithKline had a stellar year in Japan in 2011, driven by new products and surging sales of its human papillomavirus vaccine Cervarix.